Version · CLP
Version in force
Made by Regulation (EU) 2022/692 32022R0692 on EUR-Lex (external, EUR-Lex)
Version 25 of 31 recorded for CLP.
First seen by emendrix on , when it first read this version; that is not a legal date.
2 changes in this version
Consolidated versions 02008R1272-20230731 → 02008R1272-20231201. v1 is the previous version, v2 this one.
What changed
Annex III LIST OF HAZARD STATEMENTS, SUPPLEMENTAL HAZARD INFORMATION AND SUPPLEMENTAL LABEL ELEMENTS, Modified§
Not in every listWhat this means
Found in the text, but not every source lists it — the text comparison found this change; the EU's own amendment metadata does not list it. The source that does not name it is the EU's own amendment metadata. Both are shown; neither is overruled.
No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.
Text from EUR-Lex, before and after
Previous version, in force 31 July 2023 02008R1272-20230731 → this version, in force 1 December 2023 02008R1272-20231201
compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere
ANNEX III
LIST OF HAZARD STATEMENTS, SUPPLEMENTAL HAZARD INFORMATION AND SUPPLEMENTAL LABEL ELEMENTS
1. Part 1: hazard statements
… 2,942 unchanged lines …
FI Käyttöturvallisuustiedote toimitetaan pyynnöstä.
SV Säkerhetsdatablad finns att rekvirera.
EUH 211 Language BG Внимание! При пулверизация могат да се образуват опасни респирабилни капки. Не вдишвайте пулверизираната струя или мъгла.
ES ¡Atención! Al rociar pueden formarse gotas respirables peligrosas. No respirar el aerosol. ES ¡Atención! Al rociar pueden formarse gotas respirables peligrosas. No respirar el aerosol o la niebla.
CS Pozor! Při postřiku se mohou vytvářet nebezpečné respirabilní kapičky. Nevdechujte aerosoly nebo mlhu.
DA Advarsel! Der kan danne sig farlige respirable dråber, når der sprayes. Undgå indånding af spray eller tåge.
DE Achtung! Beim Sprühen können gefährliche lungengängige Tröpfchen entstehen. Aerosol oder Nebel nicht einatmen.
ET Hoiatus! Pihustamisel võivad tekkida ohtlikud sissehingatavad piisad. Pihustatud ainet või udu mitte sisse hingata.
EL Προσοχή! Κατά τον ψεκασμό μπορούν να σχηματιστούν επικίνδυνα εισπνεύσιμα σταγονίδια. Μην αναπνέετε το εκνέφωμα ή τα σταγονίδια.
EN Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
FR Attention! Des gouttelettes respirables dangereuses peuvent se former lors de la pulvérisation. Ne pas respirer les aérosols ni les brouillards.
GA Aire! D’fhéadfaí braoiníní guaiseacha inanálaithe a chruthú nuair a spraeáiltear an táirge seo. Ná hanálaigh sprae ná ceo.
HR Upozorenje! Pri prskanju mogu nastati opasne respirabilne kapljice. Ne udisati aerosol ni maglicu.
IT Attenzione! In caso di vaporizzazione possono formarsi goccioline respirabili pericolose. Non respirare i vapori o le nebbie.
LV Uzmanību! Izsmidzinot var veidoties bīstami ieelpojami pilieni. Ne smidzinājumu, ne miglu neieelpot.
LT Atsargiai! Purškiant gali susidaryti pavojingų įkvepiamų lašelių. Neįkvėpti rūko ar aerozolio.
HU Figyelem! Permetezés közben veszélyes, belélegezhető cseppek képződhetnek. A permetet vagy a ködöt nem szabad belélegezni.
MT Twissija! Jista’ jifforma qtar perikoluż li jinġibed man-nifs meta tisprejja minn dan. Tiġbidx l-isprej jew l-irxiex man-nifs.
NL Let op! Bij verneveling kunnen gevaarlijke inhaleerbare druppels worden gevormd. Spuitnevel niet inademen.
PL Uwaga! W przypadku rozpylania mogą się tworzyć niebezpieczne respirabilne kropelki. Nie wdychać rozpylonej cieczy lub mgły.
PT Atenção! Podem formar-se gotículas inaláveis perigosas ao pulverizar. Não respirar a pulverização ou névoas.
RO Avertizare! Se pot forma picături respirabile periculoase la pulverizare. Nu respirați prin pulverizare sau ceață. RO Atenție! La pulverizare, se pot forma picături respirabile periculoase. Nu inspirați vaporii, ceața sau aerosolii.
SK Pozor! Pri rozprašovaní sa môžu vytvárať nebezpečné respirabilné kvapôčky. Nevdychujte aerosóly ani hmlu.
SL Pozor! Pri razprševanju lahko nastanejo nevarne vdihljive kapljice. Ne vdihavajte razpršila ali meglic.
FI Varoitus! Vaarallisia keuhkorakkuloihin kulkeutuvia pisaroita saattaa muodostua suihkutuksen yhteydessä. Älä hengitä suihketta tai sumua.
… 46 unchanged lines …
SL Da bi se izognili tveganjem za ljudi in okolje, ravnajte v skladu z navodili za uporabo.
FI Noudata käyttöohjeita ihmisen terveydelle ja ympäristölle aiheutuvien vaarojen välttämiseksi.
SV För att undvika risker för människors hälsa och för miljön, följ bruksanvisningen.
Annex VI Harmonised classification and labelling for certain hazardous substances, Modified§
No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.
Each CAS and EC number in these tables links to its own page, which lists every entry that prints it across the acts this record holds.
39 entries added, 17 amended, 0 removed.
1 row carries no key and is not compared.
39 entries added
| Identifiers | Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | |||||||
| Index No 014-052-00-7CAS 68909-20-6EC 272-697-1 | 014-052-00-7 | silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide | 272-697-1 | 68909-20-6 | STOT RE 2 | H373 (lungs) (inhalation) | GHS08 Wng | H373 (lungs) (inhalation) | EUH066 | ||
| Index No 035-005-00-7CAS 12124-97-9EC 235-183-8 | 035-005-00-7 | ammonium bromide | 235-183-8 | 12124-97-9 | Repr. 1B Lact. STOT SE 3 STOT RE 1 Eye Irrit. 2 | H360FD H362 H336 H372 (nervous system) H319 | GHS08 GHS07 Dgr | H360FD H362 H336 H372 (nervous system) H319 | |||
| Index No 050-032-00-4CAS 2781-10-4EC 220-481-2 | 050-032-00-4 | dibutyltin bis(2-ethylhexanoate) | 220-481-2 | 2781-10-4 | Muta. 2 Repr. 1B STOT RE 1 | H341 H360FD H372 (immune system) | GHS08 Dgr | H341 H360FD H372 (immune system) | |||
| Index No 050-033-00-XCAS 1067-33-0EC 213-928-8 | 050-033-00-X | dibutyltin di(acetate) | 213-928-8 | 1067-33-0 | Muta 2 Repr. 1B STOT RE 1 | H341 H360FD H372 (immune system) | GHS08 Dgr | H341 H360FD H372 (immune system) | |||
| Index No 052-001-00-0CAS 13494-80-9EC 236-813-4 | 052-001-00-0 | tellurium | 236-813-4 | 13494-80-9 | Repr. 1B Lact. | H360Df H362 | GHS08 Dgr | H360Df H362 | |||
| Index No 052-002-00-6CAS 7446-07-3EC 231-193-1 | 052-002-00-6 | tellurium dioxide | 231-193-1 | 7446-07-3 | Repr. 1B Lact. | H360Df H362 | GHS08 Dgr | H360Df H362 | |||
| Index No 056-005-00-3CAS 13701-59-2EC 237-222-4 | 056-005-00-3 | barium diboron tetraoxide | 237-222-4 | 13701-59-2 | Repr. 1B Acute Tox. 4 Acute Tox. 3 | H360FD H332 H301 | GHS08 GHS06 Dgr | H360FD H332 H301 | inhalation: ATE = 1,5 mg/L (dusts or mists) oral: ATE = 100 mg/kg bw | ||
| Index No 601-097-00-8CAS 103-65-1EC 203-132-9 | 601-097-00-8 | Propylbenzene | 203-132-9 | 103-65-1 | Flam. Liq. 3 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 | H226 H304 H335 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H226 H304 H335 H411 | |||
| Index No 603-243-00-6CAS 1522-92-5CAS 36483-57-5EC 253-057-0 | 603-243-00-6 | 2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol | 253-057-0 | 36483-57-5; 1522-92-5 | Carc. 1B Muta. 2 | H350 H341 | GHS08 Dgr | H350 H341 | |||
| Index No 604-096-00-0CAS 51-03-6EC 200-076-7 | 604-096-00-0 | piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether | 200-076-7 | 51-03-6 | STOT SE 3 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H335 H319 H400 H410 | GHS07 GHS09 Wng | H335 H319 H410 | EUH066 | M = 1 M = 1 | |
| Index No 604-097-00-6CAS 732-26-3EC 211-989-5 | 604-097-00-6 | 2,4,6-tri-tert-butylphenol | 211-989-5 | 732-26-3 | Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1B | H360D H302 H373 (liver) H317 | GHS08 GHS07 Dgr | H360D H302 H373 (liver) H317 | oral: ATE = 500 mg/kg bw | ||
| Index No 604-098-00-1CAS 80-09-1EC 201-250-5 | 604-098-00-1 | 4,4'-sulphonyldiphenol; bisphenol S | 201-250-5 | 80-09-1 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | |||
| Index No 606-153-00-5CAS 119-61-9EC 204-337-6 | 606-153-00-5 | benzophenone | 204-337-6 | 119-61-9 | Carc. 1B | H350 | GHS08 Dgr | H350 | |||
| Index No 606-154-00-0CAS 2797-51-5EC 220-529-2 | 606-154-00-0 | quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone | 220-529-2 | 2797-51-5 | Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d H302 H373 (blood system, kidneys) H319 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H361d H302 H373 (blood system, kidneys) H319 H317 H410 | oral: ATE = 500 mg/kg bw M = 10 M = 10 | ||
| Index No 607-756-00-6CAS 5888-33-5EC 227-561-6 | 607-756-00-6 | exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate; isobornyl acrylate | 227-561-6 | 5888-33-5 | Skin Sens. 1A | H317 | GHS07 Wng | H317 | |||
| Index No 607-757-00-1CAS 1596-84-5EC 216-485-9 | 607-757-00-1 | daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid | 216-485-9 | 1596-84-5 | Carc. 2 | H351 | GHS08 Wng | H351 | |||
| Index No 607-758-00-7CAS 80-51-3EC 201-286-1 | 607-758-00-7 | 4,4'-oxydi(benzenesulphonohydrazide) | 201-286-1 | 80-51-3 | Self-react. D Aquatic Acute 1 Aquatic Chronic 1 | H242 H400 H410 | GHS02 GHS09 Dgr | H242 H410 | M = 1 M = 1 | ||
| Index No 607-759-00-2CAS 1576-35-8EC 216-407-3 | 607-759-00-2 | toluene-4-sulphonohydrazide | 216-407-3 | 1576-35-8 | Self-react. D | H242 | GHS02 Dgr | H242 | |||
| Index No 607-760-00-8CAS 15141-18-1EC 239-203-6 | 607-760-00-8 | 2-[N-ethyl-4-[(5-nitrothiazol-2-yl)azo]-m-toluidino]ethyl acetate; C.I. Disperse Blue 124 | 239-203-6 | 15141-18-1 | Skin Sens. 1A | H317 | GHS07 Wng | H317 | Skin Sens. 1A; H317: C ≥ 0,001 % | ||
| Index No 607-761-00-3CAS 375-85-9EC 206-798-9 | 607-761-00-3 | Perfluoroheptanoic acid; tridecafluoroheptanoic acid | 206-798-9 | 375-85-9 | Repr. 1B STOT RE 1 | H360D H372 (liver) | GHS08 Dgr | H360D H372 (liver) | |||
| Index No 607-762-00-9CAS 283159-90-0 | 607-762-00-9 | methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chlorophenyl)-β-alaninate; valifenalate | — | 283159-90-0 | Carc. 2 Aquatic Chronic 2 | H351 H411 | GHS08 GHS09 Wng | H351 H411 | |||
| Index No 607-763-00-4 | 607-763-00-4 | 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts | — | — | Repr. 1B Eye Irrit. 2 | H360FD H319 | GHS08 GHS07 Dgr | H360FD H319 | |||
| Index No 607-764-00-XCAS 2156592-54-8 | 607-764-00-X | 6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid | — | 2156592-54-8 | Repr. 1B Eye Irrit. 2 | H360FD H319 | GHS08 GHS07 Dgr | H360FD H319 | |||
| Index No 607-765-00-5 | 607-765-00-5 | 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid | — | — | Repr. 1B | H360FD | GHS08 Dgr | H360FD | |||
| Index No 613-341-00-0CAS 74115-24-5EC 277-728-2 | 613-341-00-0 | clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine | 277-728-2 | 74115-24-5 | Aquatic Chronic 1 | H410 | GHS09 Wng | H410 | M = 1 | ||
| Index No 613-342-00-6CAS 58-55-9EC 200-385-7 | 613-342-00-6 | theophylline; 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione | 200-385-7 | 58-55-9 | Repr. 1B | H360D | GHS08 Dgr | H360D | |||
| Index No 613-343-00-1CAS 179101-81-6 | 613-343-00-1 | pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether | — | 179101-81-6 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 1000 M = 100 | ||
| Index No 613-344-00-7CAS 15922-78-8CAS 3811-73-2EC 223-296-5EC 240-062-8 | 613-344-00-7 | Pyridine-2-thiol 1-oxide, sodium salt; pyrithione sodium; sodium pyrithione | 223-296-5; 240-062-8 | 3811-73-2; 15922-78-8 | Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 2 | H331 H311 H302 H372 (nervous system) H315 H319 H317 H400 H411 | GHS06 GHS08 GHS09 Dgr | H331 H311 H302 H372 (nervous system) H315 H319 H317 H410 | EUH070 | inhalation: ATE = 0,5 mg/L (dusts or mists) dermal: ATE = 790 mg/kg bw oral: ATE = 500 mg/kg bw M = 100 | |
| Index No 613-345-00-2CAS 108-78-1EC 203-615-4 | 613-345-00-2 | 1,3,5-triazine-2,4,6-triamine; melamine | 203-615-4 | 108-78-1 | Carc. 2 STOT RE 2 | H351 H373 (urinary tract) | GHS08 Wng | H351 H373 (urinary tract) | |||
| Index No 615-046-00-2CAS 2778-42-9EC 220-474-4 | 615-046-00-2 | 1,3-bis(1-isocyanato-1-methylethyl)benzene; [m-TMXDI] | 220-474-4 | 2778-42-9 | Resp. Sens. 1 Skin Sens. 1A | H334 H317 | GHS08 Dgr | H334 H317 | |||
| Index No 615-047-00-8CAS 3634-83-1EC 222-852-4 | 615-047-00-8 | 1,3-bis(isocyanatomethyl)benzene; [m-XDI] | 222-852-4 | 3634-83-1 | Resp. Sens. 1 Skin Sens. 1A | H334 H317 | GHS08 Dgr | H334 H317 | Skin Sens. 1A; H317: C ≥ 0,001 % | ||
| Index No 615-048-00-3CAS 2162-73-4EC 218-485-4 | 615-048-00-3 | 2,4,6-triisopropyl-m-phenylene diisocyanate | 218-485-4 | 2162-73-4 | Resp. Sens. 1 Skin Sens. 1 | H334 H317 | GHS08 Dgr | H334 H317 | |||
| Index No 615-049-00-9CAS 3173-72-6EC 221-641-4 | 615-049-00-9 | 1,5-naphthylene diisocyanate [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] | 221-641-4 | 3173-72-6 | STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3 | H335 H315 H319 H334 H317 H412 | GHS07 GHS08 Dgr | H335 H315 H319 H334 H317 H412 | |||
| Index No 615-050-00-4CAS 3173-72-6EC 221-641-4 | 615-050-00-4 | 1,5-naphthylene diisocyanate [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] | 221-641-4 | 3173-72-6 | Acute Tox. 2 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3 | H330 H335 H315 H319 H334 H317 H412 | GHS06 GHS08 Dgr | H330 H335 H315 H319 H334 H317 H412 | inhalation: ATE = 0,27 mg/L (dusts or mists) | ||
| Index No 616-237-00-3CAS 239110-15-7 | 616-237-00-3 | fluopicolide (ISO); 2,6-dichloro-N-[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide | — | 239110-15-7 | Repr. 2 | H361d | GHS08 Wng | H361d | |||
| Index No 616-238-00-9CAS 874819-71-3EC 477-690-9 | 616-238-00-9 | N-(2-nitrophenyl)phosphoric triamide | 477-690-9 | 874819-71-3 | Repr. 1B STOT RE 2 | H360Fd H373 (kidneys) | GHS08 Dgr | H360Fd H373 (kidneys) | |||
| Index No 616-239-00-4CAS 1255734-28-1 | 616-239-00-4 | N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram | — | 1255734-28-1 | Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H361f H332 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H361f H332 H317 H410 | inhalation: ATE = 2,2 mg/L (dusts or mists) M = 10 M = 1 | ||
| Index No 616-240-00-XCAS 881685-58-1 | 616-240-00-X | Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam | — | 881685-58-1 | Carc. 2 Repr. 1B Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H351 H360D H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H351 H360D H317 H410 | Repr. 1B; H360D: C ≥ 3 % M = 10 M = 10 | ||
| Index No 650-058-00-1CAS 84696-25-3EC 283-644-7 | 650-058-00-1 | Margosa, ext. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents] | 283-644-7 | 84696-25-3 | Repr. 2 Skin Sens. 1 Aquatic Chronic 1 | H361d H317 H410 | GHS08 GHS07 GHS09 Wng | H361d H317 H410 | M = 10 | ||
17 entries amended
| Identifiers | Version | Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||||
| Index No 014-001-00-9CAS 10025-78-2EC 233-042-5 | Before | 014-001-00-9 | trichlorosilane | 233-042-5 | 10025-78-2 | Flam. Liq. 1
| H224
| GHS02
GHS05
| H224
| EUH014 EUH029 | ||
| After | 014-001-00-9 | trichlorosilane | 233-042-5 | 10025-78-2 | Flam. Liq. 1 Water-react. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1AEye Dam. 1 | H224 H260 H331 H302 H314H318 | GHS02 GHS06 GHS05 Dgr | H224 H260 H331 H302 H314 | EUH014 EUH029EUH071 | inhalation: ATE = 7,6 mg/L (vapour) oral: ATE = 1000 mg/kg bw | ||
| Index No 023-001-00-8CAS 1314-62-1EC 215-239-8 | Before | 023-001-00-8 | divanadium pentaoxide; vanadium pentoxide | 215-239-8 | 1314-62-1 | Muta. 2
Repr. 2
STOT RE 1
| H341
| GHS08
| H341
| |||
| After | 023-001-00-8 | divanadium pentaoxide; vanadium pentoxide | 215-239-8 | 1314-62-1 | Muta. 2 Carc. 1B Repr. 2 Lact. Acute Tox. 3 Acute Tox. 2 STOT SE 3 STOT RE 1 Aquatic Chronic 2 | H341 H350 H361fd H362 H301 H330 H335 H372 (respiratory tract, inhalation) H411 | GHS06 GHS08 GHS09 Dgr | H341 H350 H361fd H362 H301 H330 H335 H372 (respiratory tract, inhalation) H411 | inhalation: ATE = 0,05 mg/L (dusts or mists) oral: ATE = 220 mg/kg bw | |||
| Index No 601-024-00-XCAS 103-65-1CAS 98-82-8EC 202-704-5EC 203-132-9 | Before | 601-024-00-X | 202-704-5 | 98-82-8 | Flam. Liq. 3 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 | H226 H304 H335 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H226 H304 H335 H411 | ||||
| After | 601-024-00-X | Cumene | 202-704-5 | 98-82-8 | Flam. Liq. 3 Carc. 1B Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 | H226 H350 H304 H335 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H226 H350 H304 H335 H411 | ||||
| Index No 603-014-00-0CAS 111-76-2EC 203-905-0 | Before | 603-014-00-0 | 2-butoxyethanol; ethylene glycol monobutyl ether | 203-905-0 | 111-76-2 | Acute Tox. | oral: ATE = 1200 mg/kg bw | |||||
| After | 603-014-00-0 | 2-butoxyethanol; ethylene glycol monobutyl ether | 203-905-0 | 111-76-2 | Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 | H331 H302 H315 H319 | GHS06 Dgr | H331 H302 H315 H319 | inhalation: ATE = 3 mg/L (Vapours) oral: ATE = 1200 mg/kg bw | |||
| Index No 603-107-00-6CAS 111-77-3EC 203-906-6 | Before | 603-107-00-6 | 2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether | 203-906-6 | 111-77-3 | Repr. | GHS08
| |||||
| After | 603-107-00-6 | 2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether | 203-906-6 | 111-77-3 | Repr. 1B | H360D | GHS08 Dgr | H360D | Repr. 1B; H360D: C ≥ 3 % | |||
| Index No 604-030-00-0CAS 80-05-7EC 201-245-8 | Before | 604-030-00-0 | bisphenol | 201-245-8 | 80-05-7 | Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 | H360F H335 H318 H317 | GHS08
GHS05 | H360F H335 H318 H317 | |||
| After | 604-030-00-0 | 4,4'-isopropylidenediphenol; bisphenol A | 201-245-8 | 80-05-7 | Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1Aquatic Acute 1 Aquatic Chronic 1 | H360F H335 H318 H317H400 H410 | GHS08 GHS07 GHS05 GHS09 Dgr | H360F H335 H318 H317H410 | M = 1 M = 10 | |||
| Index No 607-111-00-9CAS 15625-89-5EC 239-701-3 | Before | 607-111-00-9 | 2,2-bis(acryloyloxymethyl)butyl acrylate; trimethylolpropane triacrylate | 239-701-3 | 15625-89-5 | H319
| GHS07 Wng | H319
| D | |||
| After | 607-111-00-9 | 2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2-bis(acryloyloxymethyl)butyl acrylate; trimethylolpropane triacrylate | 239-701-3 | 15625-89-5 | Carc. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1Aquatic Acute 1 Aquatic Chronic 1 | H351 H315 H319 H317H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H315 H319 H317H410 | M = 1 M = 1 | D | ||
| Index No 607-230-00-6CAS 149-57-5EC 205-743-6 | Before | 607-230-00-6 | 2-ethylhexanoic acid | Repr. | GHS08
| |||||||
| After | 607-230-00-6 | 2-ethylhexanoic acidand its salts, with the exception of those specified elsewhere in this Annex | — | — | Repr. 1B | H360D | GHS08 Dgr | H360D | ||||
| Index No 607-253-00-1CAS 68359-37-5EC 269-855-7 | Before | 607-253-00-1 | cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate | 269-855-7 | 68359-37-5 | Acute Tox. 2 | H300
| GHS06 GHS09 Dgr | H300
| |||
| After | 607-253-00-1 | cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate | 269-855-7 | 68359-37-5 | Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H362 H330 H300 H370 (nervous system) H400 H410 | GHS06 GHS08 GHS09 Dgr | H362 H330 H300 H370 (nervous system) H410 | inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 14 mg/kg bw M = 1000000 M = 1000000 | |||
| Index No 607-254-00-7CAS 1820573-27-0CAS 68359-37-5EC 269-855-7 | Before | 607-254-00-7 | Acute Tox. 2 | H330 H300 H400 H410 | GHS06 GHS09 Dgr | H330 H300 H410 | ||||||
| After | 607-254-00-7 | beta-cyfluthrin(ISO); reaction mass of rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate | - | 1820573-27-0 | Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H362 H330 H300 H370 (nervous system) H400 H410 | GHS06 GHS08 GHS09 Dgr | H362 H330 H300 H370 (nervous system) H410 | inhalation: ATE = 0,081 mg/L (dusts or mists) oral: ATE = 11 mg/kg bw M = 1000000 M = 1000000 | |||
| Index No 607-734-00-6CAS 7216-95-7EC 404-290-3 | Before | 607-734-00-6 | pentapotassium | 404-290-3 | 7216-95-7 | Acute Tox. 4 STOT RE 2 Eye Irrit. 2 | H332 H373 (inhalation) H319 | GHS08
GHS07
| H332 H373 (inhalation) H319 | inhalation:
ATE = 1,5 | ||
| After | 607-734-00-6 | pentapotassium 2,2',2",2"',2""-(ethane-1,2-diylnitrilo)pentaacetate | 404-290-3 | 7216-95-7 | Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2 | H360D H332 H373 (inhalation) H319 | GHS08 GHS07 Dgr | H360D H332 H373 (inhalation) H319 | Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/L (dusts or mists) | |||
| Index No 607-735-00-1CAS 67-43-6EC 200-652-8 | Before | 607-735-00-1 | N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) | 200-652-8 | 67-43-6 | Acute Tox. 4 STOT RE 2 Eye Irrit. 2 | H332 H373 (inhalation) H319 | GHS08
GHS07
| H332 H373 (inhalation) H319 | inhalation:
ATE = 1,5 | ||
| After | 607-735-00-1 | N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) | 200-652-8 | 67-43-6 | Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2 | H360D H332 H373 (inhalation) H319 | GHS08 GHS07 Dgr | H360D H332 H373 (inhalation) H319 | Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/L (dusts or mists) | |||
| Index No 607-736-00-7CAS 140-01-2EC 205-391-3 | Before | 607-736-00-7 | pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate | 205-391-3 | 140-01-2 | Acute Tox. 4 STOT RE 2 | H332 H373 (inhalation) | GHS08
GHS07
| H332 H373 (inhalation) | inhalation:
ATE = 1,5 | ||
| After | 607-736-00-7 | pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate | 205-391-3 | 140-01-2 | Repr. 1B Acute Tox. 4 STOT RE 2 | H360D H332 H373 (inhalation) | GHS08 GHS07 Dgr | H360D H332 H373 (inhalation) | Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/L (dusts or mists) | |||
| Index No 608-032-00-2CAS 135410-20-7CAS 160430-64-8 | Before | 608-032-00-2 | acetamiprid (ISO); (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine | — | 135410-20-7 | Acute Tox. | ||||||
| After | 608-032-00-2 | acetamiprid (ISO); (1E)-N-[(6-chloropyridin-3-yl)methyl]-N’-cyano-N-methylethanimidamide; (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine | — | 135410-20-7160430-64-8 | Repr. 2 Acute Tox. 3 Aquatic Chronic 1 Aquatic Acute 1 | H361d H301 H410 H400 | GHS08 GHS06 GHS09 Dgr | H361d H301 H410 | oral: ATE = 140 mg/kg bw M = 10 M = 10 | |||
| Index No 609-042-00-XCAS 40487-42-1EC 254-938-2 | Before | 609-042-00-X | pendimethalin (ISO);
| 254-938-2 | 40487-42-1 | |||||||
| After | 609-042-00-X | pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene | 254-938-2 | 40487-42-1 | Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H400 H410 | GHS08 GSH09 Wng | H361d H410 | M = 100 M = 10 | |||
| Index No 613-012-00-1CAS 25057-89-0EC 246-585-8 | Before | 613-012-00-1 | bentazone | 246-585-8 | 25057-89-0 | Acute Tox. 4 | H302
H319
H317
| GHS07 Wng | H302
H319
H317
| |||
| After | 613-012-00-1 | bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide | 246-585-8 | 25057-89-0 | Repr. 2 Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1 | H361d H302 H319 H317 | GHS08 GHS07 Wng | H361d H302 H319 H317 | oral: ATE = 1600 mg/kg bw | |||
| Index No 616-164-00-7CAS 149961-52-4 | Before | 616-164-00-7 | dimoxystrobin (ISO); (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide | 149961-52-4 | Carc. 2
Repr. 2
Acute Tox. 4 | H351
| GHS08 GHS07 GHS09 Wng | H351
| ||||
| After | 616-164-00-7 | dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide | 149961-52-4 | Carc. 2 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d H332 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H361d H332 H410 | inhalation: ATE = 1,3 mg/L (dusts or mists) M = 100 M = 100 | ||||
Text from EUR-Lex, before and after
Previous version, in force 31 July 2023 02008R1272-20230731 → this version, in force 1 December 2023 02008R1272-20231201
compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere
ANNEX VI
Harmonised classification and labelling for certain hazardous substances
Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3.
… 2,488 unchanged lines …
H332
H314 EUH014 T
013-010-00-5 hydroxy aluminium bis(2,4,8,10-tetra-tert-butyl-6-hydroxy-12H-dibenzo[d, g][1.3.2]dioxaphosphocin-6-oxide) 430-650-4 151841-65-5 Aquatic Chronic 2 H411 GHS09 H411 014-001-00-9 trichlorosilane 233-042-5 10025-78-2 Flam. Liq. 1
Pyr. Liq. 1
Acute Tox. 4 *
Acute Tox. 4 *
Skin Corr. 1A H224
H250
H332 Water-react. 1
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1A
Eye Dam. 1 H224
H260
H331
H302
H314 GHS02 H314
H318 GHS02
GHS06
GHS05
GHS07
Dgr H224
H250
H332 H260
H331
H302
H314 EUH014
EUH029 *
STOT SE 3; H335: C ≥ 1 % T
014-002-00-4 silicon tetrachloride 233-054-0 10026-04-7 Eye Irrit. 2 EUH029
EUH071 inhalation:
ATE = 7,6 mg/L (vapour)
oral:
ATE = 1000 mg/kg bw 014-002-00-4 silicon tetrachloride 233-054-0 10026-04-7 Eye Irrit. 2
STOT SE 3
Skin Irrit. 2 H319
H335
… 241 unchanged lines …
Dgr H350i 014-049-00-0 trimethoxyvinylsilane; trimethoxy(vinyl)silane 220-449-8 2768-02-7 Skin Sens. 1B H317 GHS07
Wng H317 014-050-00-6 tris(2-methoxyethoxy)vinylsilane;
6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane 213-934-0 1067-53-4 Repr. 1B H360FD GHS08
Dgr H360FD 015-001-00-1 white phosphorus 231-768-7 12185-10-3 Pyr. Sol. 1 Dgr H360FD 014-052-00-7 silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide 272-697-1 68909-20-6 STOT RE 2 H373 (lungs) (inhalation) GHS08
Wng H373 (lungs) (inhalation) EUH066 015-001-00-1 white phosphorus 231-768-7 12185-10-3 Pyr. Sol. 1
Acute Tox. 2 *
Acute Tox. 2 *
Skin Corr. 1A
… 2,797 unchanged lines …
H413 022-006-00-2 titanium dioxide;
[in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 μm] 236-675-5 13463-67-7 Carc. 2 H351 (inhalation) GHS08
Wng H351 (inhalation) V, W, 10
023-001-00-8 divanadium pentaoxide;
vanadium pentoxide 215-239-8 1314-62-1 Muta. 2 023-001-00-8 divanadium pentaoxide; vanadium pentoxide 215-239-8 1314-62-1 Muta. 2
Carc. 1B
Repr. 2
Lact.
Acute Tox. 3
Acute Tox. 2
STOT SE 3
STOT RE 1
Acute Tox. 4 *
Acute Tox. 4 *
STOT SE 3
Aquatic Chronic 2 H341
H361d *** H372 **
H332
H302 H350
H361fd
H362
H301
H330
H335
H411 GHS08
GHS07 H372 (respiratory tract, inhalation)
H411 GHS06
GHS08
GHS09
Dgr H341
H361d *** H372 **
H332
H302 H350
H361fd
H362
H301
H330
H335
H411 024-001-00-0 chromium (VI) trioxide 215-607-8 1333-82-0 Ox. Sol. 1 H372 (respiratory tract, inhalation)
H411 inhalation:
ATE = 0,05 mg/L (dusts or mists)
oral:
ATE = 220 mg/kg bw 024-001-00-0 chromium (VI) trioxide 215-607-8 1333-82-0 Ox. Sol. 1
Carc. 1A
Muta. 1B Repr. 2
Acute Tox. 2 *
… 2,398 unchanged lines …
H302
H314
H317
H400 040-001-00-3 zirconium powder (pyrophoric) 231-176-9 7440-67-7 Water-react. 1 H400 035-005-00-7 ammonium bromide 235-183-8 12124-97-9 Repr. 1B
Lact.
STOT SE 3
STOT RE 1
Eye Irrit. 2 H360FD
H362
H336
H372 (nervous system)
H319 GHS08
GHS07
Dgr H360FD
H362
H336
H372 (nervous system)
H319 040-001-00-3 zirconium powder (pyrophoric) 231-176-9 7440-67-7 Water-react. 1
Pyr. Sol. 1 H260
H250 GHS02
Dgr H260
… 793 unchanged lines …
STOT RE 1 H360D
H372 (immune system) GHS08
Dgr H360D
H372 (immune system) 050-032-00-4 dibutyltin bis(2-ethylhexanoate) 220-481-2 2781-10-4 Muta. 2
Repr. 1B
STOT RE 1 H341
H360FD
H372 (immune system) GHS08
Dgr H341
H360FD
H372 (immune system) 050-033-00-X dibutyltin di(acetate) 213-928-8 1067-33-0 Muta 2
Repr. 1B
STOT RE 1 H341
H360FD
H372 (immune system) GHS08
Dgr H341
H360FD
H372 (immune system) 051-001-00-8 antimony trichloride 233-047-2 10025-91-9 Skin Corr. 1B
Aquatic Chronic 2 H314
H411 GHS05
… 36 unchanged lines …
Aquatic Chronic 3 H317
H412 GHS07
Wng H317
H412 053-001-00-3 iodine 231-442-4 7553-56-2 Acute Tox. 4 * H412 052-001-00-0 tellurium 236-813-4 13494-80-9 Repr. 1B
Lact. H360Df
H362 GHS08
Dgr H360Df
H362 052-002-00-6 tellurium dioxide 231-193-1 7446-07-3 Repr. 1B
Lact. H360Df
H362 GHS08
Dgr H360Df
H362 053-001-00-3 iodine 231-442-4 7553-56-2 Acute Tox. 4 *
Acute Tox. 4 *
Aquatic Acute 1 H332
H312
… 43 unchanged lines …
Acute Tox. 4 * H301
H332 GHS06
Dgr H301
H332 064-001-00-8 gadolinium(III)sulfite trihydrate 456-900-2 51285-81-5 Aquatic Chronic 2 H411 GHS09 H411 072-001-00-4 hafnium tetra-n-butoxide 411-740-2 22411-22-9 Eye Dam. 1 H332 056-005-00-3 barium diboron tetraoxide 237-222-4 13701-59-2 Repr. 1B
Acute Tox. 4
Acute Tox. 3 H360FD
H332
H301 GHS08
GHS06
Dgr H360FD
H332
H301 inhalation:
ATE = 1,5 mg/L (dusts or mists)
oral:
ATE = 100 mg/kg bw 064-001-00-8 gadolinium(III)sulfite trihydrate 456-900-2 51285-81-5 Aquatic Chronic 2 H411 GHS09 H411 072-001-00-4 hafnium tetra-n-butoxide 411-740-2 22411-22-9 Eye Dam. 1
Skin Sens. 1 H318
H317 GHS05
GHS07
… 1,099 unchanged lines …
H332
H373
(hearing organs)
H304 601-024-00-X cumene; [1]
propylbenzene [2] 202-704-5 [1]
203-132-9 [2] 98-82-8 [1]
103-65-1 [2] Flam. Liq. 3 H304 601-024-00-X Cumene 202-704-5 98-82-8 Flam. Liq. 3
Carc. 1B
Asp. Tox. 1
STOT SE 3
Aquatic Chronic 2 H226
H350
H304
H335
H411 GHS02
GHS08
GHS07
GHS09
Dgr H226
H350
H304
H335
H411 C
601-025-00-5 mesitylene; H411 601-025-00-5 mesitylene;
1,3,5-trimethylbenzene 203-604-4 108-67-8 Flam. Liq. 3
STOT SE 3
Aquatic Chronic 2 H226
… 583 unchanged lines …
H315
H317
H304
H410 M = 1 602-001-00-7 chloromethane; H410 M = 1 601-097-00-8 Propylbenzene 203-132-9 103-65-1 Flam. Liq. 3
Asp. Tox. 1
STOT SE 3
Aquatic Chronic 2 H226
H304
H335
H411 GHS02
GHS08
GHS07
GHS09
Dgr H226
H304
H335
H411 602-001-00-7 chloromethane;
methyl chloride 200-817-4 74-87-3 Flam. Gas 1
Press. Gas
Carc. 2
… 1,458 unchanged lines …
H319 GHS07
Wng H332
H312
H319 603-014-00-0 2-butoxyethanol;
ethylene glycol monobutyl ether 203-905-0 111-76-2 Acute Tox. 4* H319 603-014-00-0 2-butoxyethanol; ethylene glycol monobutyl ether 203-905-0 111-76-2 Acute Tox. 3
Acute Tox. 4
Skin Irrit. 2
Eye Irrit. 2 H332 Eye Irrit. 2 H331
H302
H315
H319 GHS07
Wng H332 H319 GHS06
Dgr H331
H302
H315
H319 oral: ATE = 1200 mg/kg bw 603-015-00-6 allyl alcohol 203-470-7 107-18-6 Flam. Liq. 2 H319 inhalation:
ATE = 3 mg/L (Vapours)
oral:
ATE = 1200 mg/kg bw 603-015-00-6 allyl alcohol 203-470-7 107-18-6 Flam. Liq. 2
Acute Tox. 3 *
Acute Tox. 3 *
Acute Tox. 3 *
… 893 unchanged lines …
Dgr H226
H360D *** H335
H315
H318 603-107-00-6 2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether 203-906-6 111-77-3 Repr. 2 H361d *** GHS08
Wng H361d *** 603-108-00-1 2-methylpropan-1-ol; iso-butanol 201-148-0 78-83-1 Flam. Liq. 3 H318 603-107-00-6 2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether 203-906-6 111-77-3 Repr. 1B H360D GHS08
Dgr H360D Repr. 1B; H360D: C ≥ 3 % 603-108-00-1 2-methylpropan-1-ol; iso-butanol 201-148-0 78-83-1 Flam. Liq. 3
STOT SE 3
Skin Irrit. 2
Eye Dam. 1
… 740 unchanged lines …
Dgr H350
H340 603-241-00-5 geraniol;
(2E)-3,7-dimethylocta-2,6-dien-1-ol 203-377-1 106-24-1 Skin Sens. 1 H317 GHS07
Wng H317 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 Wng H317 603-243-00-6 2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol 253-057-0 36483-57-5; 1522-92-5 Carc. 1B
Muta. 2 H350
H341 GHS08
Dgr H350
H341 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2
Acute Tox. 3 * Acute Tox. 3 *
Acute Tox. 3 * STOT RE 2 *
Skin Corr. 1B H341
… 369 unchanged lines …
H302
H335
H315
H318 604-030-00-0 bisphenol A;
4,4′-isopropylidenediphenol 201-245-8 80-05-7 Repr. 1B H318 604-030-00-0 4,4'-isopropylidenediphenol; bisphenol A 201-245-8 80-05-7 Repr. 1B
STOT SE 3
Eye Dam. 1
Skin Sens. 1 H360F Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H360F
H335
H318
H317 GHS08
GHS05 GHS07 H317
H400
H410 GHS08
GHS07
GHS05
GHS09
Dgr H360F
H335
H318
H317 604-031-00-6 guaiacol 201-964-7 90-05-1 Acute Tox. 4 * H317
H410 M = 1
M = 10 604-031-00-6 guaiacol 201-964-7 90-05-1 Acute Tox. 4 *
Eye Irrit. 2
Skin Irrit. 2 H302
H319
… 410 unchanged lines …
5912-86-7 [3] Skin Sens. 1A H317 GHS07
Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 604-095-00-5 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol;
[DBMC] 204-327-1 119-47-1 Repr. 1B H360F GHS08
Dgr H360F 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Dgr H360F 604-096-00-0 piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether 200-076-7 51-03-6 STOT SE 3
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1 H335
H319
H400
H410 GHS07
GHS09
Wng H335
H319
H410 EUH066 M = 1
M = 1 604-097-00-6 2,4,6-tri-tert-butylphenol 211-989-5 732-26-3 Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Sens. 1B H360D
H302
H373 (liver)
H317 GHS08
GHS07
Dgr H360D
H302
H373 (liver)
H317 oral:
ATE = 500 mg/kg bw 604-098-00-1 4,4'-sulphonyldiphenol; bisphenol S 201-250-5 80-09-1 Repr. 1B H360FD GHS08
Dgr H360FD 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2
Acute Tox. 3* Acute Tox. 3* Acute Tox. 3*
Skin Corr. 1B
Skin Sens. 1 H350
… 1,173 unchanged lines …
H410 GHS08
GHS09
Wng H351
H410 M = 1 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 H410 M = 1 606-153-00-5 benzophenone 204-337-6 119-61-9 Carc. 1B H350 GHS08
Dgr H350 606-154-00-0 quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone 220-529-2 2797-51-5 Carc. 2
Repr. 2
Acute Tox. 4
STOT RE 2
Eye Irrit. 2
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1 H351
H361d
H302
H373 (blood system, kidneys)
H319
H317
H400
H410 GHS08
GHS07
GHS09
Wng H351
H361d
H302
H373 (blood system, kidneys)
H319
H317
H410 oral:
ATE = 500 mg/kg bw
M = 10
M = 10 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05
Dgr H314 Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 %
Skin Irrit. 2; H315: 2 % ≤C
< 10 %
… 1,066 unchanged lines …
Wng H319
H315
H317 D
607-111-00-9 2,2-bis(acryloyloxymethyl)butyl acrylate; trimethylolpropane triacrylate 239-701-3 15625-89-5 Eye Irrit. 2 607-111-00-9 2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2-bis(acryloyloxymethyl)butyl acrylate;
trimethylolpropane triacrylate 239-701-3 15625-89-5 Carc. 2
Skin Irrit. 2
Skin Sens. 1 H319 Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H351
H315
H317 GHS07
Wng H319 H319
H317
H400
H410 GHS08
GHS07
GHS09
Wng H351
H315
H317 D H319
H317
H410 M = 1
M = 1 D
607-112-00-4 2,2-dimethyltrimethylene diacrylate; neopentyl glycol diacrylate 218-741-5 2223-82-7 Acute Tox. 3 *
Eye Irrit. 2
Skin Irrit. 2
… 830 unchanged lines …
H302
H319
H335
H315 607-230-00-6 2-ethylhexanoic acid 205-743-6 149-57-5 Repr. 2 H361d *** GHS08
Wng H361d *** 607-231-00-1 clopyralid (ISO); 3,6-dichloropyridine-2-carboxylic acid 216-935-4 1702-17-6 Eye Dam. 1 H318 GHS05 H315 607-230-00-6 2-ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex — — Repr. 1B H360D GHS08
Dgr H360D 607-231-00-1 clopyralid (ISO); 3,6-dichloropyridine-2-carboxylic acid 216-935-4 1702-17-6 Eye Dam. 1 H318 GHS05
Dgr H318 607-232-00-7 pyridate (ISO);
O-(6-chloro-3-phenylpyridazin-4-yl) S-octyl thiocarbonate 259-686-7 55512-33-9 Acute Tox. 4
Skin Irrit. 2
… 203 unchanged lines …
Dgr H330
H301
H312
H410 M=10000 607-253-00-1 cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 269-855-7 68359-37-5 Acute Tox. 2 *
Acute Tox. 3 * Aquatic Acute 1
Aquatic Chronic 1 H300
H331 H410 M=10000 607-253-00-1 cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 269-855-7 68359-37-5 Lact.
Acute Tox. 2
Acute Tox. 2
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1 H362
H330
H300
H370 (nervous system)
H400
H410 GHS06
GHS08
GHS09
Dgr H300
H331
H410 M=1000 607-254-00-7 α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; beta-cyfluthrin 269-855-7 68359-37-5 Acute Tox. 2 *
Acute Tox. 2 * Aquatic Acute 1
Aquatic Chronic 1 H330 Dgr H362
H330
H300
H370 (nervous system)
H410 inhalation:
ATE = 0,14 mg/L (dusts or mists)
oral:
ATE = 14 mg/kg bw
M = 1000000
M = 1000000 607-254-00-7 beta-cyfluthrin (ISO); reaction mass of rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate - 1820573-27-0 Lact.
Acute Tox. 2
Acute Tox. 2
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1 H362
H330
H300
H370 (nervous system)
H400
H410 GHS06
GHS08
GHS09
Dgr H330 Dgr H362
H330
H300
H410 607-255-00-2 fluroxypyr (ISO);4-amino-3,5-dichloro-6-fluoro-2-pyridyloxyacetic acid — 69377-81-7 Aquatic Chronic 3 H412 — H412 607-256-00-8 azoxystrobin (ISO); H370 (nervous system)
H410 inhalation:
ATE = 0,081 mg/L (dusts or mists)
oral:
ATE = 11 mg/kg bw
M = 1000000
M = 1000000 607-255-00-2 fluroxypyr (ISO);4-amino-3,5-dichloro-6-fluoro-2-pyridyloxyacetic acid — 69377-81-7 Aquatic Chronic 3 H412 — H412 607-256-00-8 azoxystrobin (ISO);
methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate — 131860-33-8 Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1 H331
… 2,441 unchanged lines …
H317 GHS08
GHS07
Wng H351
H317 607-734-00-6 pentapotassium 2,2’,2’’,2’’’,2’’’’-(ethane-1,2-diylnitrilo)pentaacetate 404-290-3 7216-95-7 Acute Tox. 4 STOT RE 2
Eye Irrit. 2 H332 H317 607-734-00-6 pentapotassium 2,2',2",2"',2""-(ethane-1,2-diylnitrilo)pentaacetate 404-290-3 7216-95-7 Repr. 1B
Acute Tox. 4
STOT RE 2
Eye Irrit. 2 H360D
H332
H373 (inhalation)
H319 GHS08
GHS07
Wng H332 Dgr H360D
H332
H373 (inhalation)
H319 inhalation:
ATE = 1,5 mg/l (dusts or mists) 607-735-00-1 N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) 200-652-8 67-43-6 Acute Tox. 4 STOT RE 2
Eye Irrit. 2 H332 H319 Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists) 607-735-00-1 N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) 200-652-8 67-43-6 Repr. 1B
Acute Tox. 4
STOT RE 2
Eye Irrit. 2 H360D
H332
H373 (inhalation)
H319 GHS08
GHS07
Wng H332 Dgr H360D
H332
H373 (inhalation)
H319 inhalation:
ATE = 1,5 mg/l (dusts or mists) 607-736-00-7 pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate 205-391-3 140-01-2 Acute Tox. 4
STOT RE 2 H332 H319 Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists) 607-736-00-7 pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate 205-391-3 140-01-2 Repr. 1B
Acute Tox. 4
STOT RE 2 H360D
H332
H373 (inhalation) GHS08
GHS07
Wng H332
H373 (inhalation) inhalation:
ATE = 1,5 mg/l (dusts or mists) 607-737-00-2 diisohexyl phthalate 276-090-2 71850-09-4 Repr. 1B H360FD GHS08 Dgr H360D
H332
H373 (inhalation) Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists) 607-737-00-2 diisohexyl phthalate 276-090-2 71850-09-4 Repr. 1B H360FD GHS08
Dgr H360FD 607-738-00-8 MCPA-thioethyl (ISO);
S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate 246-831-4 25319-90-8 Acute Tox. 4
STOT RE. 2
… 170 unchanged lines …
H361fd
H373 (eye)
H410 M = 10
M = 100 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 M = 100 607-756-00-6 exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate; isobornyl acrylate 227-561-6 5888-33-5 Skin Sens. 1A H317 GHS07
Wng H317 607-757-00-1 daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid 216-485-9 1596-84-5 Carc. 2 H351 GHS08
Wng H351 607-758-00-7 4,4'-oxydi(benzenesulphonohydrazide) 201-286-1 80-51-3 Self-react. D
Aquatic Acute 1
Aquatic Chronic 1 H242
H400
H410 GHS02
GHS09
Dgr H242
H410 M = 1
M = 1 607-759-00-2 toluene-4-sulphonohydrazide 216-407-3 1576-35-8 Self-react. D H242 GHS02
Dgr H242 607-760-00-8 2-[N-ethyl-4-[(5-nitrothiazol-2-yl)azo]-m-toluidino]ethyl acetate; C.I. Disperse Blue 124 239-203-6 15141-18-1 Skin Sens. 1A H317 GHS07
Wng H317 Skin Sens. 1A; H317: C ≥ 0,001 % 607-761-00-3 Perfluoroheptanoic acid; tridecafluoroheptanoic acid 206-798-9 375-85-9 Repr. 1B
STOT RE 1 H360D
H372 (liver) GHS08
Dgr H360D
H372 (liver) 607-762-00-9 methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chlorophenyl)-β-alaninate; valifenalate — 283159-90-0 Carc. 2
Aquatic Chronic 2 H351
H411 GHS08
GHS09
Wng H351
H411 607-763-00-4 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts — — Repr. 1B
Eye Irrit. 2 H360FD
H319 GHS08
GHS07
Dgr H360FD
H319 607-764-00-X 6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid — 2156592-54-8 Repr. 1B
Eye Irrit. 2 H360FD
H319 GHS08
GHS07
Dgr H360FD
H319 607-765-00-5 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid — — Repr. 1B H360FD GHS08
Dgr H360FD 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *
Eye Irrit. 2 H225
H332
… 270 unchanged lines …
Aquatic Chronic 3 H302
H412 GHS07
Wng H302
H412 608-032-00-2 acetamiprid (ISO);
(E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine — 135410-20-7 Acute Tox. 4 *
Aquatic Chronic 3 H302
H412 GHS07
Wng H302
H412 608-033-00-8 N-butyl-3-(2-chloro-4-nitrophenylhydrazono)-1-cyano-2-methylprop-1-ene-1,3-dicarboximide 407-970-8 75511-91-0 Skin Sens. 1 H412 608-032-00-2 acetamiprid (ISO); (1E)-N-[(6-chloropyridin-3-yl)methyl]-N’-cyano-N-methylethanimidamide; (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine — 135410-20-7 160430-64-8 Repr. 2
Acute Tox. 3
Aquatic Chronic 1
Aquatic Acute 1 H361d
H301
H410
H400 GHS08
GHS06
GHS09
Dgr H361d
H301
H410 oral:
ATE = 140 mg/kg bw
M = 10
M = 10 608-033-00-8 N-butyl-3-(2-chloro-4-nitrophenylhydrazono)-1-cyano-2-methylprop-1-ene-1,3-dicarboximide 407-970-8 75511-91-0 Skin Sens. 1
Aquatic Chronic 3 H317
H412 GHS07
Wng H317
… 839 unchanged lines …
H311
H300
H372
H400 dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw 609-042-00-X pendimethalin (ISO);
N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidine 254-938-2 40487-42-1 Skin Sens. 1 H400 dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw 609-042-00-X pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene 254-938-2 40487-42-1 Repr. 2
Aquatic Acute 1
Aquatic Chronic 1 H317 Aquatic Chronic 1 H361d
H400
H410 GHS07
GHS09
Wng H317
H410 609-043-00-5 quintozene (ISO); H410 GHS08
GSH09
Wng H361d
H410 M = 100
M = 10 609-043-00-5 quintozene (ISO);
pentachloronitrobenzene 201-435-0 82-68-8 Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H317
… 5,074 unchanged lines …
H411 GHS08
GHS09
Wng H361d *** H373 **
H411 613-012-00-1 bentazone (ISO);3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide 246-585-8 25057-89-0 Acute Tox. 4 * H411 613-012-00-1 bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide 246-585-8 25057-89-0 Repr. 2
Acute Tox. 4
Eye Irrit. 2
Skin Sens. 1
Aquatic Chronic 3 H302 Skin Sens. 1 H361d
H302
H319
H317
H412 GHS07
Wng H302 H317 GHS08
GHS07
Wng H361d
H302
H319
H317
H412 613-013-00-7 cyanazine (ISO);2-(4-chloro-6-ethylamino-1,3,5- triazine-2-ylamino)-2-methylpropionitrile 244-544-9 21725-46-2 Acute Tox. 4 * H317 oral: ATE = 1600 mg/kg bw 613-013-00-7 cyanazine (ISO);2-(4-chloro-6-ethylamino-1,3,5- triazine-2-ylamino)-2-methylpropionitrile 244-544-9 21725-46-2 Acute Tox. 4 *
Aquatic Acute 1
Aquatic Chronic 1 H302
H400
… 2,747 unchanged lines …
H410 inhalation: ATE = 4,85 mg/l (dusts or mists)
oral: ATE = 768 mg/kg bw
M = 1
M = 1 614-001-00-4 nicotine (ISO); M = 1 613-341-00-0 clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine 277-728-2 74115-24-5 Aquatic Chronic 1 H410 GHS09
Wng H410 M = 1 613-342-00-6 theophylline; 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione 200-385-7 58-55-9 Repr. 1B H360D GHS08
Dgr H360D 613-343-00-1 pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether — 179101-81-6 Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H317
H400
H410 GHS07
GHS09
Wng H317
H410 M = 1000
M = 100 613-344-00-7 Pyridine-2-thiol 1-oxide, sodium salt; pyrithione sodium; sodium pyrithione 223-296-5;
240-062-8 3811-73-2;
15922-78-8 Acute Tox. 3
Acute Tox. 3
Acute Tox. 4
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 2 H331
H311
H302
H372 (nervous system)
H315
H319
H317
H400
H411 GHS06
GHS08
GHS09
Dgr H331
H311
H302
H372 (nervous system)
H315
H319
H317
H410 EUH070 inhalation:
ATE = 0,5 mg/L (dusts or mists)
dermal:
ATE = 790 mg/kg bw
oral:
ATE = 500 mg/kg bw
M = 100 613-345-00-2 1,3,5-triazine-2,4,6-triamine;
melamine 203-615-4 108-78-1 Carc. 2
STOT RE 2 H351
H373 (urinary tract) GHS08
Wng H351
H373 (urinary tract) 614-001-00-4 nicotine (ISO);
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2
Acute Tox. 2
Acute Tox. 2
… 734 unchanged lines …
H413 GHS08
Dgr H334
H317
H413 616-001-00-X N, N-dimethylformamide; H413 615-046-00-2 1,3-bis(1-isocyanato-1-methylethyl)benzene; [m-TMXDI] 220-474-4 2778-42-9 Resp. Sens. 1
Skin Sens. 1A H334
H317 GHS08
Dgr H334
H317 615-047-00-8 1,3-bis(isocyanatomethyl)benzene; [m-XDI] 222-852-4 3634-83-1 Resp. Sens. 1
Skin Sens. 1A H334
H317 GHS08
Dgr H334
H317 Skin Sens. 1A; H317: C ≥ 0,001 % 615-048-00-3 2,4,6-triisopropyl-m-phenylene diisocyanate 218-485-4 2162-73-4 Resp. Sens. 1
Skin Sens. 1 H334
H317 GHS08
Dgr H334
H317 615-049-00-9 1,5-naphthylene diisocyanate
[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] 221-641-4 3173-72-6 STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3 H335
H315
H319
H334
H317
H412 GHS07
GHS08
Dgr H335
H315
H319
H334
H317
H412 615-050-00-4 1,5-naphthylene diisocyanate
[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] 221-641-4 3173-72-6 Acute Tox. 2
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3 H330
H335
H315
H319
H334
H317
H412 GHS06
GHS08
Dgr H330
H335
H315
H319
H334
H317
H412 inhalation:
ATE = 0,27 mg/L (dusts or mists) 616-001-00-X N, N-dimethylformamide;
dimethyl formamide 200-679-5 68-12-2 Repr. 1B
Acute Tox. 4 *
Acute Tox. 4 *
… 860 unchanged lines …
H411 GHS07
GHS09
Wng H315
H411 616-163-00-1 4,4'-methylenebis[N-(4-chlorophenyl)-3-hydroxynaphthalene-2-carboxamide] 430-350-3 192463-88-0 Aquatic Chronic 4 H413 — H413 616-164-00-7 dimoxystrobin (ISO);
(E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide — 149961-52-4 Carc. 2 H411 616-163-00-1 4,4'-methylenebis[N-(4-chlorophenyl)-3-hydroxynaphthalene-2-carboxamide] 430-350-3 192463-88-0 Aquatic Chronic 4 H413 — H413 616-164-00-7 dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide 149961-52-4 Carc. 2
Repr. 2
Acute Tox. 4 * Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1 H351
H361d*** H361d
H332
H400
H410 GHS08
GHS07
GHS09
Wng H351
H361d*** H361d
H332
H410 M=10 616-165-00-2 beflubutamid (ISO); H410 inhalation:
ATE = 1,3 mg/L (dusts or mists)
M = 100
M = 100 616-165-00-2 beflubutamid (ISO);
(RS)-N-benzyl-2-(α, α, α, 4-tetrafluoro-m-tolyoxy)butyramide — 113614-08-7 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
… 362 unchanged lines …
H411 GHS08
GHS09
Wng H351
H410 M = 1 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H410 M = 1 616-237-00-3 fluopicolide (ISO); 2,6-dichloro-N-[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide — 239110-15-7 Repr. 2 H361d GHS08
Wng H361d 616-238-00-9 N-(2-nitrophenyl)phosphoric triamide 477-690-9 874819-71-3 Repr. 1B
STOT RE 2 H360Fd
H373 (kidneys) GHS08
Dgr H360Fd
H373 (kidneys) 616-239-00-4 N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram — 1255734-28-1 Repr. 2
Acute Tox. 4
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1 H361f
H332
H317
H400
H410 GHS08
GHS07
GHS09
Wng H361f
H332
H317
H410 inhalation:
ATE = 2,2 mg/L (dusts or mists)
M = 10
M = 1 616-240-00-X Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam — 881685-58-1 Carc. 2
Repr. 1B
Skin Sens. 1B
Aquatic Acute 1 Aquatic Chronic 1 H351
H360D
H317
H400
H410 GHS08
GHS07
GHS09
Dgr H351
H360D
H317
H410 Repr. 1B; H360D:
C ≥ 3 %
M = 10
M = 10 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242
H225
H341 GHS02
GHS08
… 5,203 unchanged lines …
STOT RE 1 H360FD
H372 (immune system) GHS08
Dgr H360FD
H372 (immune system) 650-057-00-6 Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide] 283-644-7 84696-25-3 Aquatic Chronic 3 H412 H412 Table 3.2 H372 (immune system) 650-057-00-6 Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide] 283-644-7 84696-25-3 Aquatic Chronic 3 H412 H412 650-058-00-1 Margosa, ext. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents] 283-644-7 84696-25-3 Repr. 2
Skin Sens. 1
Aquatic Chronic 1 H361d
H317
H410 GHS08
GHS07
GHS09
Wng H361d
H317
H410 M = 10 Table 3.2
The list of harmonised classification and labelling of hazardous substances from Annex I to Directive 67/548/EEC
Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes
001-001-00-9 hydrogen 215-605-7 1333-74-0 F+; R12 F+
… 19,751 unchanged lines …
S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N
R: 50/53
S: 60-61
The full entry is committed at eu/32008R1272/CHANGELOG.md.